Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study

BACKGROUND: Sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D). Despite known sex differences in diabetes-induced cardiovascular disease (CVD), pharmacolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Abhipree, Wood, Stephen, Bell, J. Simon, De Blasio, Miles J., Ilomäki, Jenni, Ritchie, Rebecca H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166999/
https://www.ncbi.nlm.nih.gov/pubmed/37181530
http://dx.doi.org/10.1016/j.lanwpc.2023.100692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166999/
https://www.ncbi.nlm.nih.gov/pubmed/37181530
http://dx.doi.org/10.1016/j.lanwpc.2023.100692

Ejemplares similares